Novel Transcatheter Mitral Valve Prosthesis for Patients With Severe Mitral Annular Calcification

Treatment of mitral regurgitation (MR) in the setting of severe mitral annular calcification (MAC) is challenging due to the high risk for fatal atrioventricular groove disruption and significant paravalvular leak. The objective of this study was to evaluate the potential for transcatheter mitral va...

Full description

Saved in:
Bibliographic Details
Published inJournal of the American College of Cardiology Vol. 74; no. 11; pp. 1431 - 1440
Main Authors Sorajja, Paul, Gössl, Mario, Babaliaros, Vasilis, Rizik, David, Conradi, Lenard, Bae, Richard, Burke, Robert F., Schäfer, Ulrich, Lisko, John C., Riley, Robert D., Guyton, Robert, Dumonteil, Nicolas, Berthoumieu, Pierre, Tchetche, Didier, Blanke, Philipp, Cavalcante, João L., Sun, Benjamin
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 17.09.2019
Elsevier Limited
Subjects
Online AccessGet full text
ISSN0735-1097
1558-3597
1558-3597
DOI10.1016/j.jacc.2019.07.069

Cover

More Information
Summary:Treatment of mitral regurgitation (MR) in the setting of severe mitral annular calcification (MAC) is challenging due to the high risk for fatal atrioventricular groove disruption and significant paravalvular leak. The objective of this study was to evaluate the potential for transcatheter mitral valve replacement in patients with severe MAC using an anatomically designed mitral prosthesis. Nine patients (77 ± 6 years of age; 5 men) were treated with the valve, using transapical delivery performed under general anesthesia and with guidance from transesophageal echocardiography and fluoroscopy. Device implantation was successful with relief of MR in all 9 patients. There were no procedural deaths. In 1 patient, left ventricular outflow tract obstruction occurred due to malrotation of the prosthesis, and successful alcohol septal ablation was performed. During a median follow-up of 12 months (range 1 to 28 months), there was 1 cardiac death, 1 noncardiac death, no other mortality, and no prosthetic dysfunction, and MR remained absent in all treated patients. Rehospitalization for heart failure occurred in 2 patients who did not die subsequently. Clinical improvement with mild or no symptoms occurred in all patients alive at the end of follow-up. Transcatheter mitral valve replacement in severe mitral annular calcification with a dedicated prosthesis is feasible and can result in MR relief with symptom improvement. Further evaluation of this approach for these high-risk patients is warranted. [Display omitted]
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0735-1097
1558-3597
1558-3597
DOI:10.1016/j.jacc.2019.07.069